Published in J Diabetes Sci Technol on June 28, 2016
If PBMs Guard Access to Drugs, Then Quis Custodiet Ipsos Custodies? (Who Will Guard the Guardians?). J Diabetes Sci Technol (2016) 0.78
The emergence of biosimilar insulin preparations--a cause for concern? Diabetes Technol Ther (2012) 2.36
Quality of original and biosimilar epoetin products. Pharm Res (2010) 1.46
In the Biosimilar Marketplace Will There Be 50 Ways to Leave Your Insulin? J Diabetes Sci Technol (2016) 1.18
Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med (2013) 6.64
Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther (2013) 2.85
Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technol Ther (2012) 2.46
The missing element of telemedicine for diabetes: decision support software. J Diabetes Sci Technol (2009) 1.83
Time synching or time sinking? Diabetes Technol Ther (2005) 1.70
The need for separate performance goals for glucose sensors in the hypoglycemic, normoglycemic, and hyperglycemic ranges. Diabetes Care (2004) 1.55
Using telemedicine to improve outcomes in diabetes--an emerging technology. J Diabetes Sci Technol (2009) 1.52
Blood glucose meter market: this world is undergoing drastic changes. J Diabetes Sci Technol (2013) 1.51
Assisted monitoring of blood glucose: special safety needs for a new paradigm in testing glucose. J Diabetes Sci Technol (2010) 1.48
Technical aspects of the Parkes error grid. J Diabetes Sci Technol (2013) 1.41
Second insulin pump safety meeting: summary report. J Diabetes Sci Technol (2010) 1.40
A review of the security of insulin pump infusion systems. J Diabetes Sci Technol (2011) 1.34
Regulatory controversies surround blood glucose monitoring devices. J Diabetes Sci Technol (2010) 1.32
New evidence demonstrates that self-monitoring of blood glucose does not improve outcomes in type 2 diabetes-when this practice is not applied properly. J Diabetes Sci Technol (2008) 1.15
The need for clinical accuracy guidelines for blood glucose monitors. J Diabetes Sci Technol (2012) 1.14
Diabetes and telemedicine: is the technology sound, effective, cost-effective, and practical? Diabetes Care (2003) 1.11
Personalized medicine for diabetes. J Diabetes Sci Technol (2008) 1.05
SMBG out of control: the need for educating patients about control solution. Diabetes Educ (2013) 0.99
Designing an artificial pancreas system to be compatible with other medical devices. J Diabetes Sci Technol (2008) 0.99
Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol (2013) 0.97
The current status of bolus calculator decision-support software. J Diabetes Sci Technol (2012) 0.97
Technology to treat hyperglycemia in trauma. J Diabetes Sci Technol (2007) 0.94
Subcutaneous continuous glucose monitoring in severe burn patients. Crit Care Med (2007) 0.92
Patient-reported outcomes and continuous glucose monitoring: can we do better with artificial pancreas devices? Diabetes Care (2015) 0.91
Hypoglycemia begets hypoglycemia: the order effect in the ASPIRE in-clinic study. Diabetes Technol Ther (2014) 0.90
Point-of-Care Blood Glucose Meter Accuracy in the Hospital Setting. Diabetes Spectr (2014) 0.90
Improved outcomes from diabetes monitoring: the benefits of better adherence, therapy adjustments, patient education, and telemedicine support. J Diabetes Sci Technol (2012) 0.89
Twelve modern digital technologies that are transforming decision making for diabetes and all areas of health care. J Diabetes Sci Technol (2013) 0.88
Improving the safety of blood glucose monitoring. J Diabetes Sci Technol (2011) 0.86
The ASPIRE study: design and methods of an in-clinic crossover trial on the efficacy of automatic insulin pump suspension in exercise-induced hypoglycemia. J Diabetes Sci Technol (2011) 0.86
Insulin pens and new ways of insulin delivery. Diabetes Technol Ther (2013) 0.85
Spending for diabetes drugs is increasing in the United States. J Diabetes Sci Technol (2008) 0.81
The increasing incidence of diabetes in the 21st century. J Diabetes Sci Technol (2009) 0.80
Association of automated carotid IMT measurement and HbA1c in Japanese patients with coronary artery disease. Diabetes Res Clin Pract (2013) 0.79
United Kingdom prospective diabetes study follow-up studies establish a legacy effect of therapy for hyperglycemia but not hypertension. J Diabetes Sci Technol (2008) 0.79
If PBMs Guard Access to Drugs, Then Quis Custodiet Ipsos Custodies? (Who Will Guard the Guardians?). J Diabetes Sci Technol (2016) 0.78
The need for performance standards for continuous glucose monitors. J Diabetes Sci Technol (2007) 0.78
The benefits of implanted glucose sensors. J Diabetes Sci Technol (2007) 0.78
The need for a glycemia modeling comparison workshop to facilitate development of an artificial pancreas. J Diabetes Sci Technol (2010) 0.78
A sweetened beverage tax is needed to combat the obesity epidemicas well as related absenteeism and presenteeism. J Diabetes Sci Technol (2009) 0.78
Hospital diabetes: why quality of care matters to both patients and hospitals. J Diabetes Sci Technol (2011) 0.78
The beneficial effects of a Paleolithic diet on type 2 diabetes and other risk factors for cardiovascular disease. J Diabetes Sci Technol (2009) 0.77
Two Automated Techniques for Carotid Lumen Diameter Measurement: Regional versus Boundary Approaches. J Med Syst (2016) 0.76
Business and economics of diabetes. J Diabetes Sci Technol (2008) 0.76
Microdialysis of interstitial fluid for continuous glucose measurement. Diabetes Technol Ther (2003) 0.76
Glutamic Acid decarboxylase therapy for recent-onset type 1 diabetes: are we at the end or the beginning of finding a cure? J Diabetes Sci Technol (2009) 0.75
Freedom of speech and science: can companies force us to withdraw data they don't like? J Diabetes Sci Technol (2013) 0.75
Bariatric surgery for obese adolescents. J Diabetes Sci Technol (2007) 0.75
Fibroblast growth factor: will this hormone be the hemoglobin A1c for managing phosphorus balance in chronic kidney disease? J Diabetes Sci Technol (2010) 0.75
The link between diabetes, military metabolic monitoring, and NASA. Diabetes Technol Ther (2003) 0.75
Trends in FDA regulation of software to control insulin dosing. J Diabetes Sci Technol (2015) 0.75
Dirlotapide, a U.S. Food and Drug Administration-approved first-in-class obesity drug for dogs-will humans be next? J Diabetes Sci Technol (2007) 0.75
The "catalyst to better diabetes care act of 2007". J Diabetes Sci Technol (2008) 0.75
Technology for portable measurement of blood lactate. Diabetes Technol Ther (2003) 0.75
The new food and drug administration center for devices and radiological health engineering and physics laboratory and methods for testing software that controls infusion pumps. J Diabetes Sci Technol (2007) 0.75
Current, emerging, and future trends in metabolic monitoring. Diabetes Technol Ther (2002) 0.75
Performance of Blood Glucose Meters in the Low-Glucose Range: Current Evaluations Indicate That it is not Sufficient From a Clinical Point of View. Diabetes Care (2015) 0.75
The First Annual Diabetes Technology Meeting--a new forum for accelerating the development of technology to fight diabetes. Diabetes Technol Ther (2002) 0.75
An adaptive drug infusion system. Diabetes Technol Ther (2004) 0.75
Pyruvate therapy for severe hypoglycemia. Diabetes Technol Ther (2005) 0.75
European trends in diabetes technology--continuous glucose measurements and computerized information-processing tools. Diabetes Technol Ther (2002) 0.75
Well-balanced system for coronary calcium detection and volume measurement in a low resolution intravascular ultrasound videos. Comput Biol Med (2017) 0.75